Infinion Biopharma engages in the business of pharmaceutical licensing and commercialisation of high-value, innovative products in various therapeutic areas. The company has filed an IPO prospectus to sell 45 lakh equity shares to raise an undisclosed amount.
Infinion Biopharma is a research-driven life science company involved in licensing and commercialisation of a wide variety of therapeutic drugs. They are involved in developing technology combining biophysics and engineering with traditional pharmacology and biochemistry to produce high-value, innovative products.
They are engaged with several companies in the USA and UK for developing innovative healthcare products.
Infinion Biopharma Ltd. Objective
- Infinion intends to use the net proceeds from the IPO to invest in Mobius Biomedical Inc. and acquire licences for product development in skin care and women’s health products.
- A portion will be utilised to meet working capital requirements and to expand their geographical reach.
Why should you invest in Infinion Biopharma Ltd. IPO?
Here are our top reasons.
- They have developed significant business relationships with several USA and UK pharmaceutical companies for research, design, and development of a vast range of therapeutic products.
- The company developed a robust country-wide network to distribute its products to the Indian markets.
- Infinion strongly invests in research and development that helps it to receive first mover advantage in creating new drugs.
- They are expanding and in 2020, they obtained a 10.43 percent stake in UK-based research oriented company, Aurum Bioscience Ltd. (ABL).
Competitive Peers
There is no similar company in India that engages in a business similar to that of Infinion Biopharma. Hence, a strict comparison is not possible.
IPO Financials
| Particulars | FY21 | FY20 |
|---|---|---|
| Total Income | 68,987.06 | NA |
| EBITDA | NA | NA |
| EBITDA Margin (%) | NA | NA |
| Profit After Tax | 64,240.27 | 13,697.46 |
| EPS | 6.24 | 1.71 |
| ROE | NA | NA |
Know before investing
Strengths
3The company has a successful track record in patenting new innovations.
The company has obtained a licence for developing and marketing pharmaceutical products using Patent technology.
The company greatly benefits from experienced management and strong leadership of its promoters. The promoter’s relationship
Risks
3The company’s income depends on the performance of the products they develop and bring them to the market earlier than its competitors.
The company has made a net loss in the previous financials and might not be able to earn profit in the future also.
The industry is highly capital intensive.
